These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16443870)

  • 21. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Laiteerapong N; Cooper JM; Skandari MR; Clarke PM; Winn AN; Naylor RN; Huang ES
    Ann Intern Med; 2018 Feb; 168(3):170-178. PubMed ID: 29230472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL; Minshall ME
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of detecting and treating diabetic retinopathy.
    Javitt JC; Aiello LP
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):164-9. PubMed ID: 8554212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The direct medical cost of type 2 diabetes.
    Brandle M; Zhou H; Smith BR; Marriott D; Burke R; Tabaei BP; Brown MB; Herman WH
    Diabetes Care; 2003 Aug; 26(8):2300-4. PubMed ID: 12882852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaco-economic issues for diabetes therapy.
    Bottomley JM; Raymond FD
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):657-85. PubMed ID: 18054741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Bargiota A; Kourlaba G; Gourzoulidis G; Maniadakis N
    Clin Drug Investig; 2018 Jan; 38(1):67-77. PubMed ID: 29080210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
    Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
    Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
    Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
    Valentine WJ; Curtis BH; Pollock RF; Van Brunt K; Paczkowski R; Brändle M; Boye KS; Kendall DM
    Diabetes Res Clin Pract; 2015 Jul; 109(1):95-103. PubMed ID: 25989713
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.